Skip to main content

Table 2 Anatomical outcomes of infants with type 1 ROP in the two groups within 6 months after primary treatment

From: Ranibizumab injection and laser photocoagulation to treat type 1 retinopathy of prematurity after 40 weeks post menstrual age: a retrospective case series study

Variables

Group 1 (Primary IVR)

Group 2 (Primary laser)

p value

Eyes,

17

10

 

Regression of acute ROP, n (%)

15 (88%)

7 (70%)

0.326 (Fisher’s exact test)

Additional treatment, n (%)

13 (76%)

3 (30%)

0.040*(Fisher’s exact test)

Causes

ROP persistence, n

0

3

 

ROP reactivation, n

0

0

 

ROP progression, n

2

0

 

Avascularity in zone II or zone III

11

0

 

Methods

Laser, n

13

3

 

IVR, n

0

0

 

Vitreoretinal surgery, n

1

0

 

Unfavorable outcomes, n (%)

2 (12%)

0 (0%)

0.516 (Fisher’s exact test)

Temporally dragged retina over the nerve, n

2

0

 

Retinal detachment or fold, n

0

0

 
  1. GA gestational age, IVR intravitreal injection of ranibizumab, ROP retinopathy of prematurity
  2. *significant between-group difference